InMed Pharmaceuticals Inc (NASDAQ:INM) shares are trading higher by 22.6% to $6.05 during Tuesday’s session after the company announced that INM-901 reduced Alzheimer’s-related inflammation in a preclinical study.
What To Know: The study revealed a significant reduction in markers of neuroinflammation, a key driver of Alzheimer's progression. Treatment with INM-901 led to a dose-dependent decrease in pro-inflammatory cytokines like TNF-α, IL-1ß, and INF-γ, which are linked to tissue inflammation.
Additionally, high-dose treatments significantly reduced levels of neurofilament light chain, a biomarker indicative of neuronal damage in neurodegenerative diseases.
Complementary mRNA profiling confirmed decreases in neuroinflammatory genes such as GFAP, CD-33, and TLR-2, which align with the observed improvements.
Read Also: Apple’s AI Advances Can’t Offset Chinese Market Slowdown, Says Analyst
How To Buy INM Stock
By now you're likely curious about how to participate in the market for InMed Pharmaceuticals – be it to purchase shares, or even attempt to bet against the company.
In the case of InMed Pharmaceuticals, which is trading at $4.95 as of publishing time, $100 would buy you 20.2 shares of stock.
According to data from Benzinga Pro, INM has a 52-week high of $15.70 and a 52-week low of $2.41.
© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
To add Benzinga News as your preferred source on Google, click here.
